1. Activation of AMPK;2. Inhibition of RBM3 RNA-binding protein;3. Correction of DM1-associated splicing defects;4. Improvement of insulin resistance and blood glucose control. The gene discussed is RBM3; the disease is myotonic dystrophy type 1.